Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

While CF treatments drive current growth, Vertex's pipeline holds significant potential for future expansion. The company is preparing for two key drug approvals in January 2025: suzetrigine for ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

This expansion of the addressable market underscores the long-term sustainability of Vertex's CF business. Vertex's pipeline is diverse and promising, with several potential catalysts on the horizon.

The threat of a trade war between Canada and the United States has put a long-dead pipeline project back in the political spotlight — with at least one former opponent now voicing support for ...

Vertex's pipeline is diverse and promising, with several potential catalysts on the horizon. The company is making significant strides in pain management, with its lead candidate, suzetrigine (VX ...

Its founder, Nathan Anderson, informed the media that the firm had “finished the pipeline of ideas” it was working on. The closure of Hindenburg is seen in the context of political ...